Anti-CD8a Antibody, clone 1J4 ZooMAb^® Rabbit Monoclonal

We are committed to bringing you greener alternative products, which adhere to one or more of The 12 Principles of Green Chemistry. This antibody is Preservative-free, produced without the harm or sacrifice of animals and exceptionally stable to allow for ambient shipping and storage if needed and thus aligns with "Waste Prevention", "Designing Safer Chemicals" and "Design for Energy Efficiency". Click here for more information.

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

Clone 1J4 is a ZooMAb^® Rabbit recombinant monoclonal antibody that specifically detects T-cell surface glycoprotein CD8a. It targets an epitope within the extracellular domain.

His-tagged recombinant fragment corresponding to 143 amino acids within the extracellular domain from the N-terminal half of human T-cell surface glycoprotein CD8a.

Quality Control Testing

Evaluated by Western Blotting in MOLT-4 cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected CD8a in MOLT-4 cell lysate.

Tested Applications

Immunocytochemistry Analysis: A 1:100 dilution from a representative lot detected CD8a in MOLT-4 and THP-1 cells.

Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected CD8a in Human tonsil tissue sections.

Flow Cytometry Analysis: 0.1 µg from a representative lot detected CD8a in one million Human peripheral blood mononuclear cells (PBMC).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

T-cell surface glycoprotein CD8 alpha chain (UniProt: P01732; also known as T-lymphocyte differentiation antigen T8/Leu-2, CD8a) is encoded by the CD8A (also known as MAL) gene (Gene ID: 925) in human. CD8 alpha is a single-pass type I membrane glycoprotein that is synthesized with a signal peptide (aa 1-21), which is subsequently cleaved to produce the mature protein that has an extracellular domain (aa 22-182), a helical domain (aa 183-203), and a cytoplasmic tail (aa 204-235). CD8 is generally present as a heterodimer of and β chains linked by two disulfide bonds, however, it can also form homodimers. The CD8 / homodimer is expressed on a subset of / TCR-bearing T cells, NK cells, intestinal intraepithelial lymphocytes, and lymphoid dendritic cells. CD8a homodimer is reported to promote the survival and differentiation of activated lymphocytes into memory CD8 T-cells. CD8a plays an essential role in the immune response and serves multiple functions in responses against both external and internal offenses. In T-cells, it functions primarily as a co-receptor for MHC class I molecule:peptide complex. It interacts simultaneously with the T-cell receptor (TCR) and the MHC class I proteins presented by antigen presenting cells. In turn, it recruits the Src kinase LCK to the vicinity of the TCR-CD3 complex where LCK phosphorylates various substrates leading to lymphokine production, motility, adhesion, and activation of cytotoxic T-lymphocytes (CTLs). This process enables CTLs to recognize and eliminate infected cells and tumor cells. Mutations in CD8A gene are known to cause the absence of CD8+ cells leading to recurrent bacterial infections. This ZooMAb^® recombinant monoclonal antibody, generated by our propriety technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals. (Ref.: Harland, KL., et al., (2014). Nat. Commun. 5; Article 3547; Gibbings, DJ., et al. (2007). BMC Immunol. 8; 12; de la Calle-Martin, O., et al. (2001). J. Clin. Invest. 108(1); 117-123).

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

Reconstitute lyophilized antibody pellet with 25μL of ultrapure water or Phosphate Buffered Saline (PBS). Please refer to our reconstitution protocol and the specific application guidance on the suggested starting dilutions and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.